Search research articles
Contact Us
Filters
Showing results (141-150 of 176) with videos related to
Page
of 18
Sort By:
Nature Medicine
|
May 14, 2024
Author Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial
Roch Houot, Emmanuel Bachy, Guillaume Cartron, et al.
Nature Medicine
|
September 14, 2023
Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial
Roch Houot, Emmanuel Bachy, Guillaume Cartron, et al.
Blood Advances
|
June 5, 2023
Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study
Emmanuel Bachy, Kerry J Savage, Huiqiang Huang, et al.
Leukemia & Lymphoma
|
February 25, 2026
Comparative effectiveness of odronextamab monotherapy <i>versus</i> real-world systemic therapies in R/R follicular lymphoma
Emmanuel Bachy, James Harnett, Katharina Prochazka, et al.
Blood
|
June 11, 2025
Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment
Alexis Claudel, Anne-Ségolène Cottereau, Emmanuel Bachy, et al.
The Journal of Clinical Investigation
|
May 27, 2021
Chronic T cell receptor stimulation unmasks NK receptor signaling in peripheral T cell lymphomas via epigenetic reprogramming
Sylvain Carras, Dimitri Chartoire, Sylvain Mareschal, et al.
Blood Cancer Journal
|
November 7, 2024
Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma
Rossana Di Staso, Beatrice Casadei, Frederick L Locke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 25, 2019
Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study
Emmanuel Bachy, John F Seymour, Pierre Feugier, et al.
Blood
|
June 28, 2024
Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responses
Jana von Jan, Sanna Timonen, Till Braun, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 26, 2025
Health-Related Quality of Life With Odronextamab Monotherapy for Relapsed/Refractory Follicular Lymphoma in the ELM-2 Study
Benoit Tessoulin, James Harnett, Seok-Goo Cho, et al.
Page
of 18
Search research articles
Search
Showing results (141-150 of 176) with videos related to
Sort By:
Page
of 18
Nature Medicine
|
May 14, 2024
Author Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial
Roch Houot, Emmanuel Bachy, Guillaume Cartron, et al.
Nature Medicine
|
September 14, 2023
Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial
Roch Houot, Emmanuel Bachy, Guillaume Cartron, et al.
Blood Advances
|
June 5, 2023
Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study
Emmanuel Bachy, Kerry J Savage, Huiqiang Huang, et al.
Leukemia & Lymphoma
|
February 25, 2026
Comparative effectiveness of odronextamab monotherapy <i>versus</i> real-world systemic therapies in R/R follicular lymphoma
Emmanuel Bachy, James Harnett, Katharina Prochazka, et al.
Blood
|
June 11, 2025
Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment
Alexis Claudel, Anne-Ségolène Cottereau, Emmanuel Bachy, et al.
The Journal of Clinical Investigation
|
May 27, 2021
Chronic T cell receptor stimulation unmasks NK receptor signaling in peripheral T cell lymphomas via epigenetic reprogramming
Sylvain Carras, Dimitri Chartoire, Sylvain Mareschal, et al.
Blood Cancer Journal
|
November 7, 2024
Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma
Rossana Di Staso, Beatrice Casadei, Frederick L Locke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 25, 2019
Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study
Emmanuel Bachy, John F Seymour, Pierre Feugier, et al.
Blood
|
June 28, 2024
Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responses
Jana von Jan, Sanna Timonen, Till Braun, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 26, 2025
Health-Related Quality of Life With Odronextamab Monotherapy for Relapsed/Refractory Follicular Lymphoma in the ELM-2 Study
Benoit Tessoulin, James Harnett, Seok-Goo Cho, et al.
Page
of 18